8:45 Director’s Introduction and Academic Briefing
9:00 The Basics of International Trade Theory (Beata Javorcik)
10:00 Syndicate Discussion
11:15 Winners and Losers from Trade Liberalization (Beata Javorcik)
12:15 Break, followed by Lunch at 12:30
1:15 Syndicate Discussion
2:15 Europe and Global Trade (Beata Javorcik)
3:15 Syndicate Discussion
4:30 How firms use the WTO and its rules to their advantage (Beata Javorcik)
7:00 Drinks Reception followed by Dinner at 7:30
8:45 Evening Speaker: Nigel Sheail
Today is focused on International Trade. The demand and opportunities for production in many emerging markets has excited many firms keen to benefit from international trading opportunities. Today we explore the rationale for free trade and ask whether it benefits all, or just those countries who are already advanced and have an absolute advantage in production. We study who the losers from free trade are and how free trade changes the rewards to being in capital-intensive versus less- capital intensive industries. The third lecture digs deeper into the topic of international competition by providing analytical tools to understand how firms can responding to the pressures of global trade; and what one might infer about future trends. The final lecture adds an extra dose of realism and examines what happens when trade is distorted by policy. In particular, it discusses how the role of the World Trade Organization can be both a blessing and a curse.
Beata Javorcik – Syndicate Tutor
Beata Javorcik is a Professor of Economics at the Department of Economics at Oxford, and a Fellow of All Souls College. She specializes in international trade, economic development and macroeconomics. Prior to coming to Oxford, she worked for eight years at the World Bank in Washington DC where she was involved in lending operations and provided policy advice to developing countries in Central and Eastern Europe, Latin America and Asia. Her research interests focus on determinants and consequences of inflows of foreign direct in- vestment, links between exporting and firm performance, and tariff evasion. She holds a PhD in Economics from Yale University and a BA from the University of Rochester.
Nigel Sheail – Novartis
Nigel is Head of Business Development and Licensing since October 1st, 2015. He is a member of the Pharmaceutical Executive Committee and Financial Leadership Team.
Prior to joining Novartis, Nigel was Head of Business Development and Licensing for Bayer Healthcare. He also served as Head of Group M&A at Roche and Head of Licensing for their Pharma division. Nigel has been responsible for a broad range of healthcare deals from research and technology collaborations through to large M&A transactions. Academically trained as a molecular biologist, Nigel is a qualified Chartered Accountant and has held a number of functions within the Pharmaceutical industry at Bayer, Roche and GSK. In addition to his work in business development, Nigel has also worked as a global controller for research and was finance director responsible for the establishment of Roche’s operations in China which included five joint venture operating companies and a holding company. Nigel was the founding treasurer of the Swiss Pharma Licensing Group.
Nigel holds a Bachelor of Science degree in Molecular Biology with high honors from the University of Ediburgh, School of Biological Sciences and an ACA degree, ICAEW Chartered Accountant qualification.